These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1651212)

  • 1. Data monitoring committees for multicenter clinical trials sponsored by the National Institutes of Health. I. Roles and membership of data monitoring committees for trials sponsored by the National Eye Institute.
    Hawkins BS
    Control Clin Trials; 1991 Jun; 12(3):424-37. PubMed ID: 1651212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.
    Smith MA; Ungerleider RS; Korn EL; Rubinstein L; Simon R
    J Clin Oncol; 1997 Jul; 15(7):2736-43. PubMed ID: 9215848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of monitoring practices in cancer clinical trials.
    George SL
    Stat Med; 1993 Mar; 12(5-6):435-50. PubMed ID: 8493422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases.
    Ellenberg SS; Myers MW; Blackwelder WC; Hoth DF
    Stat Med; 1993 Mar; 12(5-6):461-7; discussion 469. PubMed ID: 8493424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study.
    Snowdon C; Brocklehurst P; Tasker RC; Ward Platt M; Elbourne D
    PLoS One; 2018; 13(7):e0201037. PubMed ID: 30048484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liability issues for data monitoring committee members.
    DeMets DL; Fleming TR; Rockhold F; Massie B; Merchant T; Meisel A; Mishkin B; Wittes J; Stump D; Califf R
    Clin Trials; 2004; 1(6):525-31. PubMed ID: 16279293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data monitoring boards in the pharmaceutical industry.
    Herson J
    Stat Med; 1993 Mar; 12(5-6):555-61; discussion 563. PubMed ID: 8493431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsibilities of Data Monitoring Committees: Consensus Recommendations.
    Bierer BE; Li R; Seltzer J; Sleeper LA; Frank E; Knirsch C; Aldinger CE; Levine RJ; Massaro J; Shah A; Barnes M; Snapinn S; Wittes J
    Ther Innov Regul Sci; 2016 Sep; 50(5):648-659. PubMed ID: 30231760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH.
    Geller NL; Stylianou M
    Stat Med; 1993 Mar; 12(5-6):543-51; discussion 553. PubMed ID: 8493430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Views on Emerging Issues Pertaining to Data Monitoring Committees for Adaptive Trials.
    Antonijevic Z; Gallo P; Chuang-Stein C; Dragalin V; Loewy J; Menon S; Miller ER; Morgan CC; Sanchez M
    Ther Innov Regul Sci; 2013 Jul; 47(4):495-502. PubMed ID: 30235521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues in regulatory guidelines for data monitoring committees.
    DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R
    Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing communication among data monitoring committees and institutional review boards.
    Taylor HA; Chaisson L; Sugarman J
    Clin Trials; 2008; 5(3):277-82. PubMed ID: 18559418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some historical and methodological developments in early clinical trials at the National Institutes of Health.
    Greenhouse SW
    Stat Med; 1990 Aug; 9(8):893-901; discussion 903-6. PubMed ID: 2218192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Estimate of the Benefit-Cost Impact of the FDA Guidance on Data Monitoring Committees.
    Seltzer J
    Ther Innov Regul Sci; 2015 Sep; 49(5):698-705. PubMed ID: 30227033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.
    Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL
    J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.